• Bile tract cancer patient maintains complete response for over two years
• First patient dosed in Phase 1 onCARlytics trial combination arm
• First Australian site opens for Phase 1b azer-cel trial

Imugene Limited, a clinical-stage immuno-oncology company, has announced its Quarterly Cash Flow report for the quarter ended 31 December 2024. Key highlights include:- A bile tract cancer patient in the Phase 1 MAST trial evaluating CF33-hNIS (VAXINIA) has maintained a complete response for over two years, demonstrating the potential durability of this novel oncolytic virotherapy. The Bile Tract Cancer Expansion cohort of the MAST trial also cleared its first group of three patients with no dose-limiting toxicities observed.- The first patient was dosed in the intratumoural (IT) combination arm of Imugene's Phase 1 onCARlytics (CF33-CD19) clinical trial, OASIS. The trial aims to evaluate the safety and efficacy of Imugene's CD19-expressing oncolytic virotherapy in advanced or metastatic solid tumours.- Imugene opened the first Australian site for its Phase 1b clinical trial of azer-cel (azercabtagene zapreleucel), an allogeneic CAR T-cell therapy targeting CD19 for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The trial has already shown promising initial results at US sites.- Imugene announced that an abstract on azer-cel has been accepted for a poster presentation at the 2025 Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR).- The company entered into a funding agreement with CVI Investments, Inc., to raise up to A$46 million through the issuance of convertible notes and warrants, which will support ongoing clinical trials for key programs.- Imugene also received a A$11.7 million R&D tax refund for the 2023 financial year.